Other
LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
Preclinical transdermal delivery platform for GLP-1/GIP obesity therapies advances toward formulation optimization.
Executive Summary
- LIR Life Sciences completed a comparative animal study evaluating protamine-enhanced skin permeation for semaglutide and tirzepatide.
- Topical protamine formulations demonstrated glucose-lowering responses closely aligned with subcutaneous injections in a standardized glucose tolerance model.
- Results validate a molecule-agnostic delivery platform, showing consistent performance across two leading GLP/GIP-based therapies.
- The company will use the full dataset to drive formulation optimization, dose refinement, and lead candidate selection for upcoming preclinical and regulatory-enabling studies.
- Board approved a grant of 2,260,000 RSUs to directors, officers, and consultants, subject to a 4-month and 1-day hold period.
- Findings were presented at ENDO 2026.
Material Impact
- The news provides positive preclinical validation of the transdermal delivery platform, confirming that protamine-enhanced formulations can achieve systemic exposure comparable to injections for major obesity drugs.
- However, the data remains strictly preclinical (mouse models). Translation to human efficacy, safety, and regulatory approval carries significant uncertainty and typical biotech failure rates.
- The stock has already declined ~84% from its January high, reflecting market skepticism about the long development timeline and cash requirements. This incremental R&D milestone does not alter the fundamental risk profile or provide near-term catalysts like clinical trial initiation or commercial partnerships.
- The RSU grant introduces ~44% dilution to the current share count, which offsets some of the positive scientific sentiment and increases future capital raising pressure.
SKNY · Price
Company Overview
- LIR Life Sciences Corp. (formerly Blackbird Critical Metals) is a preclinical-stage biotechnology company focused on needle-free, skin-applied delivery systems for peptide-based therapies.
- Core technology utilizes protamine-enhanced cell-penetrating peptides (CPPs) to facilitate transdermal transport of large molecules, specifically targeting GLP-1/GIP obesity treatments.
- The company has partnered with Neuland Laboratories for macromolecule synthesis and characterization, and with Resilience BioSciences for laboratory space and early-stage experimental work.
- Current development stage is preclinical, with completed animal studies validating the delivery platform's efficacy in glucose control models.
More from LIR Life Sciences Corp.
May 22, 2026 · 19:00